Corcept Therapeutics Stock (NASDAQ:CORT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$59.60

52W Range

$20.84 - $61.66

50D Avg

$44.32

200D Avg

$32.12

Market Cap

$6.19B

Avg Vol (3M)

$902.43K

Beta

0.46

Div Yield

-

CORT Company Profile


Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

352

IPO Date

Apr 14, 2004

Website

CORT Performance


CORT Financial Summary


Dec 23Dec 22Dec 21
Revenue$482.38M$401.86M$365.98M
Operating Income$107.28M$112.63M$124.48M
Net Income$106.14M$101.42M$112.51M
EBITDA$109.64M$112.63M$124.48M
Basic EPS$1.02$0.95$0.97
Diluted EPS$0.94$0.87$0.89

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 9:00 PM
Q2 24Jul 29, 24 | 9:22 PM
Q1 24May 01, 24 | 12:00 AM

Peer Comparison


TickerCompany
ANABAnaptysBio, Inc.
DICEDICE Therapeutics, Inc.
NUVBNuvation Bio Inc.
IDYAIDEAYA Biosciences, Inc.
DYNDyne Therapeutics, Inc.
NXTCNextCure, Inc.
MLYSMineralys Therapeutics, Inc.
HALOHalozyme Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
MGTXMeiraGTx Holdings plc
ERASErasca, Inc.
CERECerevel Therapeutics Holdings, Inc.
SNSESensei Biotherapeutics, Inc.
GRPHLENZ Therapeutics, Inc.
KROSKeros Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
AGIOAgios Pharmaceuticals, Inc.
INSMInsmed Incorporated
CYTKCytokinetics, Incorporated
KRTXKaruna Therapeutics, Inc.
FIXXQ32 Bio Inc.
RAREUltragenyx Pharmaceutical Inc.
MACKMerrimack Pharmaceuticals, Inc.